Novartis signs $7.8 billion Abogen biotech licensing deal
Novartis has entered a licensing agreement with China-based Abogen Biosciences worth up to $7.8 billion, marking one of the largest recent tie-ups between Big Pharma and Chinese biotech firms. The deal reflects a growing trend of Western biopharma companies turning to China to source innovation as the industry's patent cliff approaches. The agreement centers on Abogen's lead asset and signals a major shift in global biotech dealmaking.
The Atomic take
The scale of this deal shows Western pharma is now willing to bet billions on Chinese-originated drug candidates to refill pipelines before key patents expire, a sourcing strategy that was uncommon just a few years ago. Abogen's background in mRNA and lipid nanoparticle technology, built during its COVID vaccine work, suggests the lead asset could extend into chronic and age-related disease areas worth tracking. Watch whether other Big Pharma players follow with similar China-based licensing moves and how US regulators respond to the deepening dependence on Chinese biotech innovation.
Read the full story at CNBC →Know where humanity is headed.
Five forces, one investment thesis a day. Free, every weekday morning.
Get The Atomic Five